Biological effects of chicken type III interferon on expression of interferon-stimulated genes in chickens: Comparison with type I and Type II interferons

Journal of Veterinary Medical Science

Volumn 74, Issue 11, 2012, Pages 1381-1386

  Masuda, Yasumitsu ^a   Matsuda, Akiko ^a   Usui, Tatsufumi ^a   Sugai, Toru ^a   Asano, Atsushi ^a   Yamano, Yoshiaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

CEF; Chicken; Interferon; Mx; OAS

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PRIMER DNA;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHICK EMBRYO; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ESCHERICHIA COLI; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; ORTHOMYXOVIRUS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CHICK EMBRYO; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FIBROBLASTS; GENE EXPRESSION REGULATION; INTERFERONS; ORTHOMYXOVIRIDAE; REAL-TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

AVES; ESCHERICHIA COLI; GALLUS GALLUS; MAMMALIA; ORTHOMYXOVIRIDAE;

EID: 84870863365     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.11-0517     Document Type: Article

References (32)

1. Ank, N., West, H., Bartholdy, C., Eriksson, K., Thomsen, A. R. and Paludan, S. R. 2006. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80: 4501-4509. [Medline] [CrossRef]
2. Billiau, A. and Matthys, P. 2009. Interferon-γ: a historical perspective. Cytokine Growth Factor Rev. 20: 97-113. [Medline] [CrossRef]
3. Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S. T., Otte, J. M., Diebold, J., Diepolder, H., Adler, B., Auernhammer, C. J., Göke, B. and Dambacher, J. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G960-G968. [Medline] [CrossRef]
4. Doyle, S. E., Schreckhise, H., Khuu-Duong, K., Henderson, K., Rosler, R., Storey, H., Yao, L., Liu, H., Barahmand-pour, F., Sivakumar, P., Chan, C., Birks, C., Foster, D., Clegg, C. H., Wietzke-Braun, P., Mihm, S. and Klucher, K. M. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906. [Medline] [CrossRef]
5. Dumoutier, L., Lejeune, D., Hor, S., Fickenscher, H. and Renauld, J. C. 2003. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem. J. 370: 391-396. [Medline] [CrossRef]
6. Ellinwood, N. M., McCue, J. M., Gordy, P. W. and Bowen, R. A. 1998. Cloning and characterization of cDNAs for a bovine (Bos taurus) Mx protein. J. Interferon Cytokine Res. 18: 745-755. [Medline] [CrossRef]
7. Fensterl, V. and Sen, G. C. 2009. Interferons and viral infections. Biofactors 35: 14-20. [Medline] [CrossRef]
8. Goetschy, J. F., Zeller, H., Content, J. and Horisberger, M. A. 1989. Regulation of the interferon-inducible IFI-78K gene, the human equivalent of the murine Mx gene, by interferons, double-stranded RNA, certain cytokines, and viruses. J. Virol. 63: 2616-2622. [Medline]
9. Haller, O., Gao, S., von der Malsburg, A., Daumke, O. and Kochs, G. 2010. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. J. Biol. Chem. 285: 28419-28424. [Medline] [CrossRef]
10. Holzinger, D., Jorns, C., Stertz, S., Boisson-Dupuis, S., Thimme, R., Weidmann, M., Casanova, J. L., Haller, O. and Kochs, G. 2007. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J. Virol. 81: 7776-7785. [Medline] [CrossRef]
11. Hovanessian, A. G. 2007. On the discovery of interferoninducible, double-stranded RNA activated enzymes: the 2'-5′ oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev. 18: 351-361. [Medline] [CrossRef]
12. Karpala, A. J., Morris, K. R., Broadway, M. M., McWaters, P. G., O'Neil, T. E., Goossens, K. E., Lowenthal, J. W. and Bean, A. G. 2008. Molecular cloning, expression, and characterization of chicken IFN-λ. J. Interferon Cytokine Res. 28: 341-350. [Medline] [CrossRef]
13. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C. S., Reis e Sousa, C., Matsuura, Y., Fujita, T. and Akira, S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105. [Medline] [CrossRef]
14. Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H. and Donnelly, R. P. 2003. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77. [Medline] [CrossRef]
15. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4: 1009-1015. [Medline] [CrossRef]
16. Liu, S. Y., Sanchez, D. J. and Cheng, G. 2011. New developments in the induction and antiviral effectors of type I interferon. Curr. Opin. Immunol. 23: 57-64. [Medline] [CrossRef]
17. Lowenthal, J. W., Lambrecht, B., van den Berg, T. P., Andrew, M. E., Strom, A. D. and Bean, A. G. 2000. Avian cytokines-the natural approach to therapeutics. Dev. Comp. Immunol. 24: 355-365. [Medline] [CrossRef]
18. Maher, S. G., Sheikh, F., Scarzello, A. J., Romero-Weaver, A. L., Baker, D. P., Donnelly, R. P. and Gamero, A. M. 2008. IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther. 7: 1109-1115. [Medline] [CrossRef]
19. Marcello, T., Grakoui, A., Barba-Spaeth, G., Machlin, E. S., Kotenko, S. V., MacDonald, M. R. and Rice, C. M. 2006. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898. [Medline] [CrossRef]
20. Meager, A., Visvalingam, K., Dilger, P., Bryan, D. and Wadhwa, M. 2005. Biological activity of interleukins-28 and-29: comparison with type I interferons. Cytokine 31: 109-118. [Medline] [CrossRef]
21. Onoguchi, K., Yoneyama, M., Takemura, A., Akira, S., Taniguchi, T., Namiki, H. and Fujita, T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 282: 7576-7581. [Medline] [CrossRef]
22. Osterlund, P. I., Pietilä, T. E., Veckman, V., Kotenko, S. V. and Julkunen, I. 2007. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes. J. Immunol. 179: 3434-3442. [Medline]
23. Prchal, M., Pilz, A., Simma, O., Lingnau, K., von Gabain, A., Strobl, B., Müller, M. and Decker, T. 2009. Type I interferons as mediators of immune adjuvants for T-and B cell-dependent acquired immunity. Vaccine 27(Suppl. 6): G17-G20. [Medline] [CrossRef]
24. Schroder, K., Hertzog, P. J., Ravasi, T. and Hume, D. A. 2004. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189. [Medline] [CrossRef]
25. Schultz, U., Rinderle, C., Sekellick, M. J., Marcus, P. I. and Staeheli, P. 1995. Recombinant chicken interferon from Escherichia coli and transfected COS cells is biologically active. Eur. J. Biochem. 229: 73-76. [Medline] [CrossRef]
26. Schultz, U., Kaspers, B. and Staeheli, P. 2004. The interferon system of non-mammalian vertebrates. Dev. Comp. Immunol. 28: 499-508. [Medline] [CrossRef]
27. Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., Ostrander, C., Dong, D., Shin, J., Presnell, S., Fox, B., Haldeman, B., Cooper, E., Taft, D., Gilbert, T., Grant, F. J., Tackett, M., Krivan, W., McKnight, G., Clegg, C., Foster, D. and Klucher, K. M. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68. [Medline] [CrossRef]
28. Sommereyns, C., Paul, S., Staeheli, P. and Michiels, T. 2008. IFN-λ is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4: e1000017. [Medline] [CrossRef]
29. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207: 2053-2063. [Medline] [CrossRef]
30. Witte, K., Gruetz, G., Volk, H. D., Looman, A. C., Asadullah, K., Sterry, W., Sabat, R. and Wolk, K. 2009. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10: 702-714. [Medline] [CrossRef]
31. Witte, K., Witte, E., Sabat, R. and Wolk, K. 2010. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 21: 237-251. [Medline] [CrossRef]
32. Zhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L. and Hartmann, R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81: 7749-7758. [Medline] [CrossRef]